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Antioxidant supplementation for the prevention of kwashiorkor in
Malawian children: randomised, double blind, placebo controlled
trial
Heather Ciliberto, Michael Ciliberto, André Briend, Per Ashorn, Dennis Bier, Mark Manary
Abstract
Objective To evaluate the efficacy of antioxidant
supplementation in preventing kwashiorkor in a population of
Malawian children at high risk of developing kwashiorkor.
Design Prospective, double blind, placebo controlled trial
randomised by household.
Setting 8 villages in rural southern Malawi.
Participants 2372 children in 2156 households aged 1-4 years
were enrolled; 2332 completed the trial.
Intervention Daily supplementation with an antioxidant
powder containing riboflavin, vitamin E, selenium, and
N-acetylcysteine in a dose that provided about three times the
recommended dietary allowance of each nutrient or placebo
for 20 weeks.
Main outcome measures The primary outcome was the
incidence of oedema. Secondary outcomes were the rates of
change for weight and length and the number of days of
infectious symptoms.
Results 62 children developed kwashiorkor (defined by the
presence of oedema); 39/1184 (3.3%) were in the antioxidant
group and 23/1188 (1.9%) were in the placebo group (relative
risk 1.70, 95% confidence interval 0.98 to 2.42). The two groups
did not differ in rates of weight or height gain. Children who
received antioxidant supplementation did not experience less
fever, cough, or diarrhoea.
Conclusions Antioxidant supplementation at the dose
provided did not prevent the onset of kwashiorkor. This finding
does not support the hypothesis that depletion of vitamin E,
selenium, cysteine, or riboflavin has a role in the development
of kwashiorkor.
Introduction
Kwashiorkor is a form of severe childhood malnutrition defined
by oedema and characterised by anorexia, irritability, ulcerating
dermatosis, and fatty infiltration of the liver.1 2 The hypothesis
that kwashiorkor is a consequence of dietary protein deficiency
and hypoalbuminemia has been advanced widely.3 However, this
hypothesis has been challenged by data showing that oedema
resolves before serum albumin concentrations change,4 children
with kwashiorkor do not ingest any less protein than children
with marasmus,5 and oedema dissipates while the children are
being fed a low protein diet.6
Golden and Ramdath proposed that kwashiorkor results
from an imbalance between the production of free radicals and
their safe disposal.7 This theory is supported by the observations
that blood concentrations of vitamin E derivatives, glutathione,
and red cell antioxidant enzymes are lower in children with
kwashiorkor than in marasmic children.8–10 There is biochemical
evidence of excessive lipid peroxidation in kwashiorkor,11 as well
as excessive quantities of oxidised amino acids.12 In a small clini-
cal trial, the administration of N-acetylcysteine, a glutathione
precursor, resulted in more rapid resolution of oedema in
kwashiorkor.13 These associations between oxidative stress and
kwashiorkor indicate that antioxidant depletion may cause
kwashiorkor, and the onset of kwashiorkor may therefore be
prevented with antioxidant supplementation.
Malawi is a rural country in Africa where 56% of childhood
deaths are attributed to malnutrition and kwashiorkor is the pre-
dominant form of severe malnutrition. A large population
survey of more than 25 000 children conducted in 1994 found
the prevalence of kwashiorkor to be 2.5% in healthy children
aged 1-3 years.14
This study tested the hypothesis that antioxidant supplemen-
tation would prevent kwashiorkor in children in Malawi.
Methods
We conducted our study from November 2003 to March 2004 in
eight villages in the Machinga district of southern Malawi. We
chose this district because it was found to have the highest preva-
lence of kwashiorkor in southern Malawi.14 The habitual diet of
people in this region is based on maize and is supplemented with
fish. Most villagers are subsistence farmers, but they have
difficulties growing crops in the sandy soil surrounding the lake.
About half of the villagers have access to a source of clean water.
Almost everyone in this area lives in mud huts. Health care in
these villages is provided mainly by health surveillance assistants,
government employees with one year of healthcare training in
first aid and simple health maintenance. The nearest health cen-
tre is at least 40 km from the villages.
Participants
Enrolment was open to all children aged 12-48 months who did
not have any severe chronic illness and were not oedematous at
the time of enrolment. The study was scheduled to coincide with
the rainy season, just before the annual harvest, when children
are most likely to develop kwashiorkor. We enrolled children
from 3 November to 11 November 2003 and followed them for
20 weeks. All carers gave written and verbal informed consent
before enrolment. Carers were able to cease participation at any
point in person or by refraining from attending their scheduled
follow-up visits.
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Study design
The experimental design was a double blind, placebo controlled
trial, randomised by household, in accordance with the
European Commission’s guidelines for good clinical practice.15
The trial is reported in accordance with the CONSORT
guidelines for clustered randomised trials.16
On enrolment, the carer of the participating child was ques-
tioned about demographic data. The children were checked for
oedema and had their height, weight, and circumference of their
middle upper arm measured. We recorded these data on a num-
bered card that had been marked with one of eight letters corre-
sponding to the letters on placebo or active powder bottles. Four
of the letters corresponded to a placebo and four to an antioxi-
dant formulation. The carer received an appointment card with
their child’s study number written on it for presentation at
follow-up. We assigned the letter designating the type of powder
on each data card prospectively to that data card by using a com-
puterised random number generator blocked in groups of 200.
All investigators and caretakers were blind as to which letters
were placebo and which contained antioxidants. Siblings
received data cards with the same letter to avoid confusion by the
carer about which type of powder each child received. On enrol-
ment, we instructed carers how to use the powder and reminded
them periodically at follow-up visits. We instructed them to place
one scoop of powder into a small plastic cup every day, which
was provided for them. They were then told to add
approximately 30 ml of water or just enough to dissolve the
powder with vigorous agitation. Powder bottles contained a
week’s supply and went to carers at enrolment and then every
four weeks.
The intervention group received a citrus flavoured powder
containing 1.8 mg riboflavin, 23 mg Vitamin E (d- tocopheryl
acetate), 55 g selenium (sodium selenate), and 300 mg
N-acetylcysteine per 6 g (one measuring scoop). The dose of
each of the antioxidants was about three times the recom-
mended dietary allowance for children aged 1-3 years.17 18 Ribo-
flavin was added to the antioxidant supplement because it is
necessary for the reduction of glutathione. The control group
received an identical looking, citrus flavoured powder with no
active ingredients. In preliminary trials, all children in this age
group found the drink acceptable (n = 300). Both the placebo
and antioxidant powders were developed and produced for the
study by Nutriset (Malaunay, France).
Subjects returned for follow-up with the study team (two
investigators and two senior nurses) to a central meeting point in
their village every two weeks for 20 weeks. The study team
recorded presence of oedema and any history of fever, cough, or
diarrhoea in the preceding two weeks at every visit. Mothers were
asked if the child had a rash or vomiting to monitor for an
adverse reaction. We recorded the children’s weight and circum-
ference of their middle upper arm at every other visit. We meas-
ured height three times at enrolment and three times at each
child’s last visit and used the average of the three recorded
heights in our analysis. Before enrolment, study investigators and
senior project nurses received training in an inpatient nutritional
unit to assess oedema. During the study, a study investigator
assessed oedema by compressing the skin over both of the child’s
fourth metatarsal bones with a firm finger for 10 seconds and
looking for evidence of pitting. All children who were found by
an investigator to have oedema also had oedema checked inde-
pendently by a senior project nurse.
If both a senior project nurse and an investigator judged a
child to have oedema, a diagnosis of kwashiorkor was made and
the child was removed from the study. Depending on the clinical
condition of the oedematous child, he or she was either brought
to the nearest nutritional rehabilitation unit for standard
treatment or offered home based therapy with ready to use
therapeutic food that has been shown to be effective in treating
children with kwashiorkor without anorexia or severe infectious
symptoms.19
Health surveillance assistants residing in the participating
villages encouraged participation and compliance with the study
protocol and were available to help mothers if any concerns
arose about the powder.
A subset of the participants gave urine specimens to be
checked for compliance. Urine samples came from 21 children
who developed oedema in February and March 2004 and from
24 randomly selected non-oedematous children. A laboratory
technician checked urine for ultraviolet fluorescence indicating
the presence of riboflavin.20
The primary outcome of this study was the incidence of
oedema. Secondary outcomes were the rates of change in
weight; gain in circumference of the middle upper arm and
length of the arm; and the number of days of fever, cough, and
diarrhoea.
Statistical analysis
We estimated a sample size of 1400 children to give a 5% type 1
error and 80% power to detect a reduction in the prevalence of
kwashiorkor from 4% to 1.3%, assuming a dropout rate of 10%.
The code for the letter designation of the powder (antioxidant or
placebo) was held by the manufacturer and not available to any
members of the study team until clinical follow-up was complete
and all data had been entered, checked, and sealed in an
electronic database. We used intention to treat analysis. We
assessed the difference in the primary outcome, development of
kwashiorkor, between the two groups by mathematical
modelling using generalised estimating equations extension of
logistic regression (SAS, version 9, Cary, North Carolina).21 22
This statistical method accounts for the clustering of participants
by family and village as well as for the effect of the covariates of
age and anthropometric indices. The result can be expressed as
a relative risk with 95% confidence interval. We used Student’s t
test to compare secondary outcomes and the Wilcoxon rank sum
test to compare days of fever, cough, and diarrhoea between the
two groups.
Results
We randomly assigned 2372 children from 2156 households to
receive antioxidant powder (n = 1184) or placebo (n = 1188; fig-
ure).We observed no adverse events in either group. Forty (1.7%)
children were lost to follow-up. Dropout rates were equally
distributed for both groups, and 28 (70%) of those who were lost
to follow-up were children who moved from the geographical
area of the study (figure). The demographic and nutritional
characteristics of the children who dropped out were similar to
those who completed the study. The demographic and
nutritional characteristics of the children on enrolment were
similar for both groups (table 1).
Of the 2372 children enrolled in the study, 62 (2.6%)
developed oedema; 39/1184 (3.3%) of these children received
antioxidants and 23/1188 (1.9%) received placebo (relative risk
1.70, 95% confidence interval 0.98 to 2.42). No siblings were
found to have kwashiorkor. Seven children died from illness or
injury without oedema, three in the antioxidant supplement
group and four in the placebo group. Secondary outcomes did
not differ significantly (table 2), including rates of weight and
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height gain and the number of days of fever, cough, and
diarrhoea.
Children who developed oedema were younger and had sig-
nificantly lower anthropometric indices than those who did not
(table 3). Children who developed oedema reported a larger
fraction of days with fever in the 14 days before oedema
appeared than children who did not (5.5% v 2.4%; difference
3.1%, 2.9% to 3.3%), as well as more cough (2.7% v 1.8%; 0.9%,
0.6% to 1.2%) and diarrhoea (5.8% v 2.0%; 3.8%, 3.4% to 4.2%).
We collected 45 urine specimens, 21 from children with
oedema and 24 from children without oedema. All 30 children
who received the antioxidant supplement tested positive for
fluorescence (100%, 88% to 100%). All 15 children assigned to
receiving placebo tested negative for fluorescence.
Of the 62 children who developed oedema, 60 received the
home based treatment with ready to use therapeutic food and
two were brought to a nutritional rehabilitation unit. Sixty one
children subsequently recovered.
Discussion
Supplementation with riboflavin, vitamin E, selenium, and
N-acetylcysteine at a level of three times the recommended
dietary allowance did not prevent kwashiorkor in a susceptible
population, nor was it associated with better growth or less fever,
cough, or diarrhoea.
Advantages of the study design
The study design ensured that the two groups were similar in
every characteristic other than the type of supplement they
received. The actual sample size was much larger than planned
because we had underestimated the populations of the
participating villages. This study population represents rural
African children who develop kwashiorkor around the time they
are weaned from the breast. It may not be representative of other
children at risk of developing kwashiorkor. HIV rates, for exam-
ple, are likely to be much lower in this population than in urban
African populations. Children under 12 months were not




Households assigned to receive
antioxidant (n=1074; 966 with 
1 child, 106 with 2 children, 
and 2 with 3 children)
Did not complete 20
 weeks of follow-up
 (n=19; 17 households
 with 1 child, and 2
 with 2 children)
Moved (n=13)
Did not like taste (n=1)
Unknown (n=2)
Carer unable to
 bring child (n=3)
Did not complete 20
 weeks of follow-up
 (n=18; 17 households
 with 1 child, and 1




 bring child (n=2)
Households assigned to receive
placebo (n=1082; 978 with 
1 child, 102 with 2 children,
and 2 with 3 children)
Households that completed 
participation in the study 
(n=1055; 949 with 1 child,
104 with 2 children, 
and 2 with 3 children)
Households that completed 
participation in the study 
(n=1064; 961 with 1 child,
101 with 2 children, 
and 2 with 3 children)
Flow of participants through the trial
Table 1 Baseline characteristics of the 2372 randomised participants,




No (%) of boys 578 (49) 576 (49)
Mean (SD) age in months 28.2 (10.6) 28.5 (10.4)
Mean (SD) weight for age z score −1.4 (1.0) −1.4 (1.0)
Mean (SD) height for age z score −1.7 (1.3) −1.6 (1.3)
Mean (SD) weight for height z
score
−0.5 (0.9) −0.5 (0.9)
Mean (SD) circumference of middle
upper arm in cm
14.8 (1.3) 14.8 (1.3)
No (%) of children still breast
feeding
477 (40) 450 (38)
Mean (SD) age when breast
feeding was stopped in months
23.6 (6.2) 24.0 (5.9)
No (%) of children whose mother
is alive
1180 (100) 1183 (100)
No (%) of children whose father is
alive
1145 (97) 1153 (97)
No (%) with access to clean water 636 (54) 658 (55)
No (%) of children in whose
houses grass was used as a
roofing material
1125 (95) 1123 (95)
Table 2 Secondary outcomes (by intention to treat) in children receiving





(n=1188) Difference (95% CI)
Mean (SD) weight gain
during 20 weeks in
g/kg/day
0.5 (0.5) 0.5 (0.4) 0.0 (−0.1 to 0.1)
Mean (SD) height gain
during 20 weeks in
mm/day
0.2 (0.2) 0.2 (0.3) 0.0 (−0.1 to 0.1)
Mean (SD) gain in
circumference of the
middle upper arm
during 20 weeks in
mm/day
0.0 (0.1) 0.0 (0.1) 0.0 (−0.1 to 0.1)
No (%) of days of cough 3142 (1.9) 2899 (1.8) 0.1% (0.0 to 0.2)
No (%) of days of fever 4099 (2.5) 3982 (2.4) 0.1% (0.0 to 0.2)
No (%) of days of
diarrhoea
3410 (2.1) 3372 (2.1) 0.0% (−0.1 to 0.1)
Mean (SD) final weight
for age z score
−1.4 (1.0) −1.4 (1.0) 0.0 (−0.1 to 0.1)
Mean (SD) final height
for age z score
−1.8 (1.2) −1.8 (1.2) 0.0 (−0.1 to 0.1)
Mean (SD) final weight
for height z score
−0.4 (0.8) −0.4 (0.8) 0.0 (−0.1 to 0.1)
Table 3 Comparison of demographic and nutritional characteristics at






(n=2310) Difference (95% CI)
No (%) of boys 26 (42) 1128 (49) 7% (−6 to 20)
Mean (SD) age in months 19.8 (7.7) 28.6 (10.5) 8.8 (6.2 to 11.4)
Mean (SD) weight for age
z score
−2.0 (1.1) −1.4 (1.0) 0.6 (0.3 to 0.9)
Mean (SD) height for age
z score
−2.0 (1.3) −1.6 (1.3) 0.4 (0.1 to 0.7)
Mean (SD) weight for
height z score
−1.0 (1.0) −0.5 (0.9) 0.5 (0.3 to 0.7)
No (%)of children whose
mother is alive
61 (98) 2302 (100) 1%
No (%)of children whose
father is alive
60 (97) 2238 (97) 0
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Role of HIV infection
HIV infection predisposes children to develop severe malnutri-
tion, although this is more commonly manifest as marasmus
than kwashiorkor. Among a population of underweight rural
Malawian children in an adjoining district aged 2-4 years, 1%
were infected with HIV.23 Therefore, if we assume that among our
population of healthy children the prevalence of HIV infection
was 0.5%, then about 12 HIV infected children would have par-
ticipated in our study. Although it is likely that a few of the chil-
dren who developed kwashiorkor in this study were infected with
HIV, this represents less than 20% of the 62 cases of kwashiorkor.
Oedema as a clinical sign
In Malawi, oedema is a common complaint at health centres and
hospitals, and more than 98% of it is the result of kwashiorkor.24
The children in this study who developed oedema did not have
pallor of their conjunctiva or clinical evidence of severe anaemia.
The study team gained the impression that many of the children
found to have oedema had associated findings suggestive of
kwashiorkor, such as hair discoloration and dermatosis, and their
oedema resolved with nutritional therapy. This evidence shows
that the oedema seen in this study was the result of kwashiorkor.
Compliance
It was not possible for study staff directly to observe children tak-
ing the powder daily, but the small subset of children who had
urine tested for excess riboflavin, which was present in the anti-
oxidant powder but not the placebo, indicated that compliance
was excellent. Children showed enthusiasm at their appoint-
ments to collect their powder bottles, and mothers did not report
that their children were reluctant to drink the supplement. The
health surveillance assistants provided regular encouragement
and reminders to mothers to comply. This evidence indicates
that compliance was high.
Role of antioxidants in preventing kwashiorkor
The “negative” results of this study made us speculate if a larger
antioxidant dose is needed to prevent kwashiorkor. The dose of
antioxidants given in this study corresponded to an amount
three times greater than the recommended dietary allowance,
and the supplement was taken in addition to their habitual diet.
Children should therefore have received enough of these dietary
antioxidants to fulfil their dietary requirements. If larger doses of
this antioxidant supplementation were able to prevent
kwashiorkor a trend should have emerged of fewer cases of
kwashiorkor in the children receiving antioxidants, rather than
more cases as was observed here.
Meaning of findings
Our findings are remarkable in light of the previously described
associations between kwashiorkor and deficiency in essential
antioxidants such as vitamin E,9 selenium,10 and glutathione8 and
evidence of having excessive oxidative stress.12 These previous
studies were comparisons of biochemical variables in small
groups of severely ill, malnourished children who had been
admitted to hospital. Our study was a prospective trial investigat-
ing the role of antioxidants in the aetiology of kwashiorkor and
indicates that antioxidant depletion may be a consequence
rather than a cause of kwashiorkor.
Kwashiorkor and environmental factors
Environment, particularly diet, certainly has an important role in
the pathogenesis of kwashiorkor; the condition is not seen in
children with an adequate nutritional intake. Intrinsic character-
istics of the host may also be required for the development of
kwashiorkor. It is possible variant isozymes or variations in con-
centrations of enzymes in the metabolic pathways permit the
development of kwashiorkor in children with poor diets.
Differences in the pattern of amino acid concentrations between
children with kwashiorkor and marasmus have been used to
propose this.25 In addition to dietary and nutritional investiga-
tions, genetic mapping techniques to delineate host factors may
prove useful to unravelling the enigma of kwashiorkor.
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